Avadhesha Surolia

Prof. Dr. Avadhesha Surolia

Molecular Biophysics Unit, Indian Institute of Science, Bangalore
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2017 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
NJNisha Grandhi Jayaprakash
Nisha Grandhi Jayaprakash
ASAvadhesha Surolia
Avadhesha Surolia
Glycosylation constitutes one of the most common, ubiquitous and complex forms of post-translational modification. It commences with the synthesis of the protein and plays a significant role in deciding its folded state, oligomerization and thus its function. Recent studies have demonstrated that N-linked glycans help proteins to fold as the stability and folding kinetics are altered with the removal of the glycans from them. Several studies have shown that it alters not only the thermodynamic stability but also the structural features of the folded proteins modulating their interactions and functions. Their inhibition and perturbations have been implicated in diseases from diabetes to degenerative disorders. The intent of this review is to provide insight into the recent advancements in the general understanding on the aspect of glycosylation driven stability of proteins that is imperative to their function and finally their role in health and disease states.

18 May 2015 in Scientific Reports
Verified
Journal Article
Open access
NANuzhat Ahsan
Nuzhat Ahsan
SMSatyendra Mishra
Satyendra Mishra
MJManish Kumar Jain
Manish Kumar Jain
ASAvadhesha Surolia
Avadhesha Surolia
SGSarika Gupta
Sarika Gupta
Accumulating evidence suggests that deposition of neurotoxic α-synuclein aggregates in the brain during the development of neurodegenerative diseases like Parkinson’s disease can be curbed by anti-aggregation strategies that either disrupt or eliminate toxic aggregates. Curcumin, a dietary polyphenol exhibits anti-amyloid activity but the use of this polyphenol is limited owing to its instability. As chemical modifications in curcumin confiscate this limitation, such efforts are intensively performed to discover molecules with similar but enhanced stability and superior properties. This study focuses on the inhibitory effect of two stable analogs of curcumin viz. curcumin pyrazole and curcumin isoxazole and their derivatives against α-synuclein aggregation, fibrillization and toxicity. Employing biochemical, biophysical and cell based assays we discovered that curcumin pyrazole (3) and its derivative N-(3-Nitrophenylpyrazole) curcumin (15) exhibit remarkable potency in not only arresting fibrillization and disrupting preformed fibrils but also preventing formation of A11 conformation in the protein that imparts toxic effects. Compounds 3 and 15 also decreased neurotoxicity associated with fast aggregating A53T mutant form of α-synuclein. These two analogues of curcumin described here may therefore be useful therapeutic inhibitors for the treatment of α-synuclein amyloidosis and toxicity in Parkinson’s disease and other synucleinopathies.

10 December 2013 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
VVV Vijayan
V Vijayan
MKM Khandelwal
M Khandelwal
KMK Manglani
K Manglani
SGSarika Gupta
Sarika Gupta
ASAvadhesha Surolia
Avadhesha Surolia

16 January 2024 in Cellular & Molecular Biology Letters
Verified
Journal Article
Open access
PDF file
NANuzhat Ahsan
Nuzhat Ahsan
MSMohd Shariq
Mohd Shariq
ASAvadhesha Surolia
Avadhesha Surolia
RRReshmi Raj
Reshmi Raj
MKMohammad Firoz Khan
Mohammad Firoz Khan
PKPramod Kumar
Pramod Kumar
TRIM proteins are characterized by their conserved N-terminal RING, B-box, and coiled-coil domains. These proteins are efficient regulators of autophagy, apoptosis, and innate immune responses and confer immunity against viruses and bacteria. TRIMs function as receptors or scaffold proteins that target substrates for autophagy-mediated degradation. Most TRIMs interact with the BECN1-ULK1 complex to form TRIMosomes, thereby efficiently targeting substrates to autophagosomes. They regulate the functions of ATG proteins through physical interactions or ubiquitination. TRIMs affect the lipidation of MAP1LC3B1 to form MAP1LC3B2, which is a prerequisite for phagophore and autophagosome formation. In addition, they regulate MTOR kinase and TFEB, thereby regulating the expression of ATG genes. TRIM proteins are efficient regulators of apoptosis and are crucial for regulating cell proliferation and tumor formation. Many TRIM proteins regulate intrinsic and extrinsic apoptosis via the cell surface receptors TGFBR2, TNFRSF1A, and FAS. Mitochondria modulate the anti- and proapoptotic functions of BCL2, BAX, BAK1, and CYCS. These proteins use a multipronged approach to regulate the intrinsic and extrinsic apoptotic pathways, culminating in coordinated activation or inhibition of the initiator and executor CASPs. Furthermore, TRIMs can have a dual effect in determining cell fate and are therefore crucial for cellular homeostasis. In this review, we discuss mechanistic insights into the role of TRIM proteins in regulating autophagy and apoptosis, which can be used to better understand cellular physiology. These findings can be used to develop therapeutic interventions to prevent or treat multiple genetic and infectious diseases.Graphical Abstract

1 February 2011 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
RTRakshamani Tripathi
Rakshamani Tripathi
TSTanmoy Samadder
Tanmoy Samadder
SGSarika Gupta
Sarika Gupta
ASAvadhesha Surolia
Avadhesha Surolia
CSChandrima Shaha
Chandrima Shaha
Use of chemotherapeutic drug cisplatin is limited because of its toxicity. Therefore, efforts continue for the discovery of novel combination therapies with cisplatin to reduce its effective treatment dose. This study evaluates the potential of fisetin, a flavonoid, to increase cisplatin cytotoxicity in human embryonal carcinoma NT2/D1 cells. Addition of fisetin to cisplatin enhanced cisplatin cytoxicity in vitro at four times lower dose than that required by cisplatin monotherapy for similar cytotoxic effects. Cisplatin, fisetin monotherapy, and addition of fisetin to cisplatin in a combination increased FasL expression. Cisplatin and fisetin as single agents activated caspases-8 and -3 and caspases-9 and -7, respectively, whereas combination treatment activated all 4 caspases. Increases in p53 and p21 and decreases in cyclin B1 and survivin occurred, all effects being more exaggerated with the combination. Fisetin, with or without cisplatin, increased expression of proapoptotic protein Bak and induced its mitochondrial oligomerization. Bid truncation and mitochondrial translocation of Bid and p53 was induced by fisetin in the presence or absence of cisplatin. Downregulation of p53 by short hairpin RNA during drug treatment decreased p21 levels but caused survivin increase, thus reducing cell death. Upstream to p53, inhibition of p38 phosphorylation reduced p53 phosphorylation and cell death. In a NT2/D1 mouse xenograft model, combination therapy was most effective in reducing tumor size. In summary, findings of this study suggest that addition of fisetin to cisplatin activates both the mitochondrial and the cell death receptor pathway and could be a promising regimen for the elimination of embryonal carcinoma cells. Mol Cancer Ther; 10(2); 255–68. ©2011 AACR.

10 October 2013 in Biochemistry
Verified
Journal Article
Closed access
SCSoumyananda Chakraborti
Soumyananda Chakraborti
GDGopa Dhar
Gopa Dhar
VDVishnu Dwivedi
Vishnu Dwivedi
ADAmlan Das
Amlan Das
APAsim Poddar
Asim Poddar
BBBhabatarak Bhattacharyya
Bhabatarak Bhattacharyya